Stock BCRX BIOCRYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.16 USD 0.00% Intraday chart for BioCryst Pharmaceuticals, Inc. -6.09% -30.55%
Apr. 17 BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil MT
Apr. 17 BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
BioCryst Launches Orladeyo (Berotralstat) in Italy
BioCryst Pharmaceuticals Sees FY23, FY24 Orladeyo Sales Topping Prior Forecast; Eyes 2024 Operating Profit
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)
Koersalarm: aandeel Pharvaris blijft stijgen
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise
BioCryst Pharmaceuticals Receives Argentine Regulatory Approval for Orladeyo
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina
BioCryst Pharmaceuticals Says Hereditary Angioedema Treatment Gets Marketing Authorization in Spain
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO
BioCryst Says Trial Data Show Treatment With Orladeyo Leads to Reduction of Hereditary Angioedema Attacks
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCRX Stock
  4. News BioCryst Pharmaceuticals, Inc.
  5. Other languages